Incyte Corp
INCY76.305USD
+0.715+0.95%
Market hours （ET）Quotes delayed by 15 min
14.81BMarket Cap
696.41P/E TTM
More Details of Incyte Corp Company
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Company Info
Ticker SymbolINCY
Company nameIncyte Corp
IPO dateDec 06, 1993
CEOMr. Bill Meury
Number of employees2617
Security typeOrdinary Share
Fiscal year-endDec 06
Address1801 Augustine Cut-Off
CityWILMINGTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code19803
Phone13024986700
Websitehttps://www.incyte.com/
Ticker SymbolINCY
IPO dateDec 06, 1993
CEOMr. Bill Meury
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.62M
-3.14%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
278.77K
--
Ms. Christiana Stamoulis
Ms. Christiana Stamoulis
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
263.82K
-1.25%
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
146.88K
+2.00%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
144.77K
+1.77%
Ms. Paula J. Swain
Ms. Paula J. Swain
Executive Vice President - Human Resources
Executive Vice President - Human Resources
106.48K
-0.80%
Mr. Michael James Morrissey
Mr. Michael James Morrissey
Executive Vice President, Head - Global Technical Operations
Executive Vice President, Head - Global Technical Operations
86.16K
+5.70%
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
66.08K
+3.96%
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
50.10K
+5.29%
Dr. Susanne Schaffert, Ph.D.
Dr. Susanne Schaffert, Ph.D.
Independent Director
Independent Director
37.95K
+4.60%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.62M
-3.14%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
278.77K
--
Ms. Christiana Stamoulis
Ms. Christiana Stamoulis
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
263.82K
-1.25%
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
146.88K
+2.00%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
144.77K
+1.77%
Ms. Paula J. Swain
Ms. Paula J. Swain
Executive Vice President - Human Resources
Executive Vice President - Human Resources
106.48K
-0.80%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
JAKAFI revenues
709.41M
67.38%
OPZELURA revenues
118.70M
11.27%
JAKAVI product royalty revenues
92.14M
8.75%
OLUMIANT product royalty revenues
30.80M
2.93%
MINJUVI revenues
29.55M
2.81%
Other
72.28M
6.87%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
JAKAFI revenues
709.41M
67.38%
OPZELURA revenues
118.70M
11.27%
JAKAVI product royalty revenues
92.14M
8.75%
OLUMIANT product royalty revenues
30.80M
2.93%
MINJUVI revenues
29.55M
2.81%
Other
72.28M
6.87%
Shareholding Stats
Updated: Sat, Jul 19
Updated: Sat, Jul 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
15.61%
The Vanguard Group, Inc.
10.20%
Dodge & Cox
7.61%
BlackRock Institutional Trust Company, N.A.
6.10%
State Street Global Advisors (US)
5.14%
Other
55.34%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
15.61%
The Vanguard Group, Inc.
10.20%
Dodge & Cox
7.61%
BlackRock Institutional Trust Company, N.A.
6.10%
State Street Global Advisors (US)
5.14%
Other
55.34%
Shareholder Types
Shareholders
Proportion
Investment Advisor
37.07%
Investment Advisor/Hedge Fund
35.74%
Hedge Fund
21.03%
Pension Fund
3.11%
Individual Investor
2.16%
Research Firm
1.99%
Bank and Trust
1.17%
Sovereign Wealth Fund
1.00%
Venture Capital
0.22%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1417
201.03M
102.93%
+1.34M
2025Q1
1457
199.01M
102.81%
-12.15M
2024Q4
1448
191.80M
99.11%
-19.23M
2024Q3
1401
192.85M
100.02%
-35.92M
2024Q2
1385
209.06M
108.78%
-39.98M
2024Q1
1357
227.85M
101.54%
-21.15M
2023Q4
1323
228.89M
102.19%
-14.49M
2023Q3
1300
224.25M
100.13%
-17.63M
2023Q2
1306
220.30M
98.76%
-17.67M
2023Q1
1294
227.74M
102.15%
-615.23K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
30.49M
15.75%
+984.00
+0.00%
Jun 30, 2025
The Vanguard Group, Inc.
19.91M
10.29%
+403.13K
+2.07%
Mar 31, 2025
Dodge & Cox
14.86M
7.68%
-55.30K
-0.37%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
11.92M
6.16%
+257.27K
+2.21%
Mar 31, 2025
State Street Global Advisors (US)
10.04M
5.18%
+4.32K
+0.04%
Mar 31, 2025
AQR Capital Management, LLC
6.74M
3.48%
+3.23M
+92.31%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.21M
2.17%
+167.91K
+4.16%
Mar 31, 2025
Renaissance Technologies LLC
3.71M
1.92%
-377.20K
-9.23%
Mar 31, 2025
LSV Asset Management
3.64M
1.88%
+170.48K
+4.92%
Mar 31, 2025
Invesco Capital Management LLC
2.74M
1.42%
+98.11K
+3.71%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
4.03%
First Trust NYSE Arca Biotechnology Index Fund
3.76%
Invesco Biotechnology & Genome ETF
2.77%
SPDR S&P Biotech ETF
2.41%
Bushido Capital US Equity ETF
2.11%
VanEck Biotech ETF
2.07%
Strategas Global Policy Opportunities ETF
1.91%
Virtus LifeSci Biotech Products ETF
1.9%
Invesco S&P 500 Equal Weight Health Care ETF
1.64%
ROBO Global Healthcare Technology & Innovation ETF
1.6%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion4.03%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.76%
Invesco Biotechnology & Genome ETF
Proportion2.77%
SPDR S&P Biotech ETF
Proportion2.41%
Bushido Capital US Equity ETF
Proportion2.11%
VanEck Biotech ETF
Proportion2.07%
Strategas Global Policy Opportunities ETF
Proportion1.91%
Virtus LifeSci Biotech Products ETF
Proportion1.9%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.64%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.6%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
